title: Anticonvulsant effect of dexmedetomidine in a rat model of self-sustaining status epilepticus with prolonged amygdala stimulation.
abstract: Status epilepticus (SE), leading to 27 percent mortality in adult patients, becomes refractory to firstline intravenous diazepam, with prolonged seizure duration. The mechanism could be attributed to the declined inhibitory action of GABA; therefore, alternative medications acting on other targets are necessary. The aim of the present study was to examine whether DEX, a highly specific central α2-adrenoreceptor agonist, could show the anticonvulsant effect on self-sustaining SE (SSSE), and to explore the involved mechanisms. Five minutes after SSSE, which was induced in adult Wistar rats by constant amygdala stimulation for 25 min, DEX was injected intraperitoneally at two dosages (50/100 μg/kg). The number and cumulative time of repeated seizures were recorded; the levels of Glu/GABA and glutathione/malondialdehyde (GSH/MDA) in hippocampus tissue were detected. The results showed that DEX effectively decreased the number and cumulative time of repeated seizures, alleviated the levels of Glu and GSH/MDA in hippocampus tissue, but no effect was detected on the level of GABA, suggesting that DEX could be a potential agent for the treatment of SSSE, the possible mechanisms were antioxidation and inhibition of the Glu release.
authors.affiliation: Key Laboratory of Neurology of Hebei Province, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
authors.forename: Min-Chen
authors.initials: MC
authors.lastname: Kan
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Wang
authors.forename: Gen-Dong
authors.initials: GD
authors.lastname: Yao
authors.forename: Jun-Tao
authors.initials: JT
authors.lastname: Li
authors.forename: Tao
authors.initials: T
authors.lastname: Xie
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Wen-Qun
authors.initials: WQ
authors.lastname: Ma
mesh_terms: D058647:Adrenergic alpha-2 Receptor Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D000679:Amygdala / Q000503:physiopathology*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D020927:Dexmedetomidine / Q000494:pharmacology* / Q000627:therapeutic use; D004558:Electric Stimulation; D018698:Glutamic Acid / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013226:Status Epilepticus / Q000188:drug therapy / Q000503:physiopathology*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000927:Anticonvulsants; D018698:Glutamic Acid; D008315:Malondialdehyde; D005680:gamma-Aminobutyric Acid; D020927:Dexmedetomidine; D005978:Glutathione